DalsnaFinance

Bridgebio Pharma Inc $BBIO

Health Care

Russell 1000 California
Create a scorecard
$68.12
+0.38 (+0.56%)
As of Oct 22, 2026, 9:29 PM EDT · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 5, 2026, the first target we tracked for BBIO.

Bridgebio Pharma Inc (BBIO) is trading up at $68.12 (+0.56%), as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.

IPO: June 27, 2019 · $17.00 offering · NASDAQ · View IPO details →

Analyst price targets on BBIO

Current price targets from 2 firms average $110 — 61% above the current $68.1. Each is tracked to its date and scored the same way a member's call is.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Bridgebio Pharma Inc revenue & net income history (FY2017–FY2025)

RevenueNet incomeNet margin (right axis, %)
$502.1M−$111.4M−$724.9MFY2017 net income: −$30.6M'17FY2018 net income: −$130.7M'18FY2019 revenue: $40.6MFY2019 net income: −$260.6M · Net margin −642.5%'19FY2020 revenue: $8.25MFY2020 net income: −$448.7M · Net margin −5439.7%'20FY2021 revenue: $69.7MFY2021 net income: −$562.5M · Net margin −806.9%'21FY2022 revenue: $77.6MFY2022 net income: −$481.2M · Net margin −619.7%'22FY2023 revenue: $9.30MFY2023 net income: −$643.2M · Net margin −6913.9%'23FY2024 revenue: $221.9MFY2024 net income: −$535.8M · Net margin −241.4%'24FY2025 revenue: $502.1MFY2025 net income: −$724.9M · Net margin −144.4%'25−100%−50%0%50%FY2019 net margin: −642.5% (off the scale, which stops at −100.0%)FY2020 net margin: −5439.7% (off the scale, which stops at −100.0%)FY2021 net margin: −806.9% (off the scale, which stops at −100.0%)FY2022 net margin: −619.7% (off the scale, which stops at −100.0%)FY2023 net margin: −6913.9% (off the scale, which stops at −100.0%)FY2024 net margin: −241.4% (off the scale, which stops at −100.0%)FY2025 net margin: −144.4% (off the scale, which stops at −100.0%)
Bridgebio Pharma Inc annual financial statements
FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue——$40.6M$8.25M$69.7M$77.6M$9.30M$221.9M$502.1M
Growth (year over year)———−79.7%+745.1%+11.4%−88.0%+2285.3%+126.3%
Gross profit————$66.6M$74.2M$6.86M$218.0M$481.1M
Gross margin————95.5%95.6%73.7%98.3%95.8%
Operating income−$43.9M−$183.7M−$266.2M−$474.5M−$576.6M−$512.2M−$607.4M−$593.0M−$523.4M
Operating margin——−656.4%−5752.0%−827.1%−659.6%−6528.8%−267.2%−104.2%
Net income−$30.6M−$130.7M−$260.6M−$448.7M−$562.5M−$481.2M−$643.2M−$535.8M−$724.9M
Net margin——−642.5%−5439.7%−806.9%−619.7%−6913.9%−241.4%−144.4%
EPS (diluted)−$1.00−$2.12−$2.48−$3.80−$3.90−$3.26−$3.95−$2.88−$3.78
Balance sheet
Cash and equivalents$92.0M$436.1M$363.8M$356.1M$393.8M$376.7M$375.9M$681.1M$570.1M
Total assets—$464.9M$631.7M$703.6M$1.01B$623.0M$546.4M$919.3M$936.0M
Total liabilities—$87.6M$155.7M$595.7M$1.88B$1.87B$1.89B$2.38B$3.01B
Long-term debt—$54.5M$91.8M$92.4M$430.8M$431.0M$446.4M$437.3M$2.01B
Shareholders' equity$85.9M$314.9M$408.5M$57.9M−$870.4M−$1.25B−$1.35B−$1.47B−$2.09B
Cash flow
Operating cash flow−$40.5M−$136.6M−$253.6M−$399.7M−$497.9M−$419.5M−$527.7M−$520.7M−$445.9M
Capital expenditure$464.0K$2.18M$2.64M$7.52M$13.2M$4.82M$1.31M$933.0K$1.10M
Free cash flow−$41.0M−$138.8M−$256.2M−$407.2M−$511.2M−$424.3M−$529.0M−$521.7M−$447.0M
Dividends paid$1.15M—$997.0K——————
Share buybacks———$75.0M$200.0M$0$0$0$48.3M

From Bridgebio Pharma Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Bridgebio Pharma Inc

Headquarters
Palo Alto, California From SEC filings, Oct 2026

Recent News (16)

More Health Care stocks

Browse all companies →